Skip to content

Clinical study on Sleep Rhythm Capsules in sleep disturbance

A Randomized, double blind, placebo controlled, multicentric, interventional Prospective, clinical Study to evaluate efficacy and safety of Sleep Rhythm Capsules (SRC) in healthy participants with mild to moderate sleep disturbances - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070841
Enrollment
60
Registered
2024-07-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Sleep Rhythm Capsules (SRC): 2 Capsules at bedtime daily with water for 30 days Control Intervention1: Placebo Capsule: 2 Capsules at bedtime daily with water for 30 days

Sponsors

Transformative Learning Solutions Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Participants aged greater than or equal to 21 and less than 65 years at the time of obtaining written informed consent 2. Participants with score between 7-21 on ISI (Insomnia severity index) 3. Participants willing to sign inform consent form and ready to follow the study protocol requirements 4. A female participant who is of reproductive potential has a negative pregnancy test and agrees to use contraception throughout study period

Exclusion criteria

Exclusion criteria: 1. Participants with history or diagnosis of secondary sleep disorder (any other underlying medical or surgical condition diagnosed on the basis of history and clinical examination by the investigator) 2. Participants with history of any neurological disorder causing interference in sleep 3. Participants with history of bipolar disorder, psychotic disorder, or posttraumatic stress disorder, or current psychiatric disorder that requires medication 4. Participants with On-going depression & generalized anxiety disorder 5. Participants with history of drug or alcohol addiction or abuse within the past 12 months 6. Participants with habit of smoking Cigarette (Average of more than 5 cigarettes per day over the last 5 years) 7. Participants with known history of hepatitis B and or C 8. Participants with history of malignancy less than or equal to 5 years prior to study participation 9. Participants with shift work disorders and other psychiatric disorders which need medication 10. Participants with known hypersensitivity to any of the ingredients of study products 11. Participants with other conditions, which in the opinion of the investigators, makes the participant unsuitable for enrolment or could interfere with his/her participation in, and completion of the protocol

Design outcomes

Primary

MeasureTime frame
1. Change in sleep parameters [Onset of sleep latency (SOL), Sleep Efficiency (SE), Total Bed time (TBT), Total Sleep Time (TST), Wake after Sleep Onset (WASO), Light Sleep, Deep Sleep, REM Sleep,] using Actigraphy 2. Change in sleep efficiency (Total sleep time/ Time in bed X 100) time of sleep onset, number of awakenings and wake time after sleep onset, (as per participant diary). Timepoint: Baseline visit, Day 7, Day 15, and Day 30

Secondary

MeasureTime frame
1.Change in severity of sleep disturbance using Insomnia Severity Index 2 Change in daytime fatigue using Fatigue Severity Scale (FSS) 3.Change in daytime mood, ability to function at work, concentration 4. Change in Quality of sleep on Pittsburgh Sleep Quality Index (PSQI) 5. Change in stress assessed on perceived stress scale (PSS) 6. Global assessment for overall change (CGI I) 7. Assessment of non habit forming property of the study products 8. Change in feeling of relaxation, calmness, deep sleep on VAS 9. Assessment of Restless thoughts, racing thoughts before sleep 10. Change in quality of life by assessing WHO QOL 11. Change in day time drowsiness, grogginess or brain fog 12. Assessment of safety and tolerability of study products Timepoint: Baseline visit, Day 7, Day 15, and Day 30

Countries

India

Contacts

Public ContactDr Sanjay Tamoli

Transformative Learning Solutions Pvt Ltd

satyendra.kumar@transformative.in09891253516

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026